The use of bevacizumab among women with metastatic breast cancer: A survey on clinical practice and the ongoing controversy

Bevacizumab Treatment for Solid Tumors

(2011) Daniel F. Hayes   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Treatment-Related Mortality With Bevacizumab in Cancer Patients

(2011) Vishal Ranpura et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer

(2011) Nicholas J. Robert et al.   JOURNAL OF CLINICAL ONCOLOGY

Congestive Heart Failure Risk in Patients With Breast Cancer Treated With Bevacizumab

(2011) Toni K. Choueiri et al.   JOURNAL OF CLINICAL ONCOLOGY

In the End What Matters Most? A Review of Clinical Endpoints in Advanced Breast Cancer

(2011) S. Verma et al.   ONCOLOGIST

Cancer Statistics, 2010

(2010) A. Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer

(2010) David W. Miles et al.   JOURNAL OF CLINICAL ONCOLOGY

The function of vascular endothelial growth factor

(2009) Bonnie J. Nieves et al.   BIOFACTORS

Breast Cancer Metastasis: Challenges and Opportunities

(2009) J. Lu et al.   CANCER RESEARCH

Independent Review of E2100: A Phase III Trial of Bevacizumab Plus Paclitaxel Versus Paclitaxel in Women With Metastatic Breast Cancer

(2009) Robert Gray et al.   JOURNAL OF CLINICAL ONCOLOGY